What Is Dulaglutide? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. Dulaglutide is FDA-approved only for specific type 2 diabetes and cardiovascular-risk uses. Products sold online as dulaglutide, Trulicity alternatives, compounded GLP-1, research-use dulaglutide, or “weight-loss GLP-1” products may carry safety, quality, legal, and regulatory risks.
Quick answer
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, usually shortened to GLP-1 receptor agonist. It is sold under the brand name Trulicity. Dulaglutide is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. It is also FDA-approved to reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Dulaglutide can reduce HbA1c and often causes modest weight loss, but it is not FDA-approved as an obesity or cosmetic weight-loss drug.
Key facts about Dulaglutide
| Question | Answer |
|---|---|
| What is dulaglutide? | A once-weekly GLP-1 receptor agonist used for type 2 diabetes and cardiovascular-risk reduction in certain adults with type 2 diabetes. |
| Brand name | Trulicity. |
| Other names | Dulaglutide injection, Trulicity injection, GLP-1 receptor agonist, GLP-1 RA. |
| Drug class | GLP-1 receptor agonist / incretin mimetic / antidiabetic peptide drug. |
| Main mechanism | Activates GLP-1 receptors to increase glucose-dependent insulin secretion, reduce glucagon secretion, slow gastric emptying, and promote satiety. |
| FDA-approved? | Yes. |
| FDA-approved uses | Improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes; reduce major cardiovascular event risk in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. |
| Weight-loss approved? | No. Dulaglutide is not FDA-approved as a weight-loss or obesity medication. |
| Main evidence | AWARD glycemic-control trials, pediatric type 2 diabetes trial, and REWIND cardiovascular outcomes trial. |
| Human evidence level | Strong for approved type 2 diabetes and cardiovascular-risk indications; weaker for obesity-only or cosmetic weight-loss claims. |
| Common side effects | Nausea, vomiting, diarrhea, abdominal pain, decreased appetite, indigestion, constipation, injection-site reactions, and possible hypoglycemia when combined with insulin or sulfonylureas. |
| Boxed warning | Risk of thyroid C-cell tumors based on rodent data; contraindicated in people with personal or family history of medullary thyroid carcinoma or MEN2. |
| Sports status | GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Athletes should verify current status through official anti-doping resources. |
| Main safety concern | Thyroid C-cell tumor warning, pancreatitis risk, severe gastrointestinal disease concerns, gallbladder disease, kidney injury from dehydration, hypoglycemia with certain diabetes drugs, hypersensitivity, and misuse of unapproved online GLP-1 products. |
What is Dulaglutide?
Dulaglutide is a GLP-1 receptor agonist. It is a peptide-based injectable medication designed to mimic the activity of GLP-1, an incretin hormone involved in blood-sugar regulation and appetite signaling.
Dulaglutide is sold under the brand name Trulicity.
The DailyMed Trulicity label states that Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. It is also indicated to reduce major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
The key distinction:
Dulaglutide is an FDA-approved diabetes and cardiovascular-risk medication, not a general weight-loss, bodybuilding, or anti-aging peptide.
How does Dulaglutide work?
Dulaglutide activates the GLP-1 receptor.
GLP-1 receptor activation affects several metabolic pathways:
- Increases glucose-dependent insulin secretion
- Reduces inappropriate glucagon secretion
- Slows gastric emptying
- Increases satiety
- Helps reduce post-meal glucose spikes
- Supports improved HbA1c in type 2 diabetes
In plain English:
Dulaglutide helps the body handle blood sugar more effectively after meals and can make some people feel full sooner.
That explains why dulaglutide can improve diabetes control and why some people lose weight while using it.
However, dulaglutide is not the same as newer obesity-focused GLP-1 drugs.
| Drug | Main receptor target | FDA-approved obesity indication? |
|---|---|---|
| Dulaglutide / Trulicity | GLP-1 receptor | No |
| Semaglutide / Wegovy | GLP-1 receptor | Yes |
| Tirzepatide / Zepbound | GIP receptor + GLP-1 receptor | Yes |
| Liraglutide / Saxenda | GLP-1 receptor | Yes |
| Retatrutide | GIP receptor + GLP-1 receptor + glucagon receptor | No, investigational |
| Mazdutide | GLP-1 receptor + glucagon receptor | Not FDA-approved; approved in China for specific uses |
The practical interpretation:
Dulaglutide belongs in the GLP-1 diabetes-drug category. It may reduce weight, but it is not FDA-approved as a dedicated obesity drug.
What is Dulaglutide used for?
Dulaglutide has clear approved uses and several common non-approved claims.
| Use | Evidence level | What is known | What is not known | |---|---|---| | Type 2 diabetes in adults | Strong evidence / FDA-approved | Dulaglutide improves glycemic control when used with diet and exercise. | It is not for type 1 diabetes or diabetic ketoacidosis. | | Type 2 diabetes in children 10 years and older | Strong evidence / FDA-approved | A pediatric trial showed improved glycemic control versus placebo. | Safety and effectiveness are not established in children under 10. | | Cardiovascular-risk reduction in adults with type 2 diabetes | Strong evidence / FDA-approved | REWIND showed reduced major adverse cardiovascular events. | It is not a general heart-disease drug for people without the approved diabetes context. | | Weight loss | Secondary effect / not obesity-approved | Some people lose weight on dulaglutide. | It is not FDA-approved for obesity or cosmetic weight loss. | | Prediabetes | Not established as approved use | GLP-1 biology may affect glucose metabolism. | Dulaglutide is not approved for prediabetes alone. | | Type 1 diabetes | Not recommended / not approved | GLP-1 effects require functioning beta-cell context. | It is not a substitute for insulin. | | Anti-aging / longevity | Unsupported | Metabolic improvement may affect health risk in diabetes. | Dulaglutide is not an anti-aging therapy. | | Bodybuilding / casual cutting | Unsupported and medically inappropriate | Appetite effects may attract misuse. | It is not a physique drug and may create safety risks. | | Online research-use dulaglutide | High risk | Sellers may market GLP-1 products online. | Quality, sterility, identity, dose, and legality may be unknown. |
What does the research show?
FDA-approved type 2 diabetes evidence
Dulaglutide’s core evidence is in type 2 diabetes.
The DailyMed Trulicity label lists dulaglutide as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes.
The AWARD clinical-trial program evaluated dulaglutide across multiple type 2 diabetes treatment settings, including monotherapy, add-on therapy, comparison with insulin glargine, comparison with liraglutide, and add-on therapy to other diabetes drugs.
A PubMed AWARD-6 trial found that once-weekly dulaglutide was non-inferior to once-daily liraglutide for HbA1c reduction, with a similar safety and tolerability profile.
A PubMed AWARD-2 trial reported that once-weekly dulaglutide 1.5 mg demonstrated greater HbA1c reduction and weight loss compared with daily insulin glargine without forced titration.
The practical interpretation:
Dulaglutide has strong diabetes evidence. It is not a speculative peptide. It is an established GLP-1 receptor agonist drug.
Pediatric type 2 diabetes evidence
Dulaglutide is also approved for pediatric patients 10 years and older with type 2 diabetes.
A New England Journal of Medicine trial and PubMed record reported that once-weekly dulaglutide was superior to placebo for improving glycemic control through 26 weeks in youths with type 2 diabetes.
The practical interpretation:
Dulaglutide has pediatric type 2 diabetes evidence, but this does not make it a general pediatric weight-loss drug.
Cardiovascular outcomes evidence
Dulaglutide has major cardiovascular outcomes evidence from the REWIND trial.
A Lancet REWIND trial and PubMed record evaluated dulaglutide in people with type 2 diabetes and a range of cardiovascular risk profiles. The trial assessed whether dulaglutide reduced major adverse cardiovascular events when added to existing diabetes therapy.
The DailyMed label reflects this evidence by listing dulaglutide for reducing the risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
The practical interpretation:
Dulaglutide is one of the GLP-1 drugs with real cardiovascular-outcomes evidence, not just glucose-lowering evidence.
Weight-loss evidence
Dulaglutide can lead to weight loss in some patients, mainly because GLP-1 receptor activation can reduce appetite and slow gastric emptying.
However, the distinction is important:
Dulaglutide is not FDA-approved for chronic weight management.
The Mayo Clinic dulaglutide page describes dulaglutide as a prescription medicine for type 2 diabetes that also lowers cardiovascular risk in patients with diabetes and heart or blood vessel problems.
The practical interpretation:
Weight loss can happen with dulaglutide, but calling it a weight-loss peptide without the diabetes and cardiovascular context is misleading.
Safety evidence and boxed warning
Dulaglutide has a boxed warning.
The FDA Trulicity label states that dulaglutide caused thyroid C-cell tumors in rats and that it is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.
The DailyMed Medication Guide states that Trulicity should not be used in people with a personal or family history of medullary thyroid carcinoma or in people with multiple endocrine neoplasia syndrome type 2.
The practical interpretation:
Dulaglutide is FDA-approved, but it is not low-risk. The boxed warning and contraindications matter.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “Dulaglutide is a GLP-1 receptor agonist.” | Supported | Dulaglutide is an FDA-approved GLP-1 receptor agonist. |
| “Dulaglutide is the same as Trulicity.” | Supported | Trulicity is the brand name for dulaglutide injection. |
| “Dulaglutide treats type 2 diabetes.” | Supported / FDA-approved | It is approved to improve glycemic control in adults and children 10 years and older with type 2 diabetes. |
| “Dulaglutide reduces cardiovascular event risk.” | Supported / FDA-approved | It is approved to reduce major adverse cardiovascular events in certain adults with type 2 diabetes. |
| “Dulaglutide is FDA-approved for weight loss.” | False | It is not FDA-approved as an obesity or chronic weight-management medication. |
| “Dulaglutide is the same as semaglutide.” | False | Both are GLP-1 receptor agonists, but they are different drugs with different labels, dosing, and evidence. |
| “Dulaglutide is the same as tirzepatide.” | False | Tirzepatide targets GIP and GLP-1 receptors; dulaglutide targets GLP-1 receptors. |
| “Dulaglutide is safe because it is a peptide.” | False | It has boxed warnings, contraindications, and serious possible adverse effects. |
| “Dulaglutide treats type 1 diabetes.” | False | It is not for type 1 diabetes or diabetic ketoacidosis. |
| “Research-use dulaglutide is equivalent to Trulicity.” | False | Online research products may differ in identity, purity, sterility, dose, quality, and legality. |
Is Dulaglutide FDA-approved?
Yes. Dulaglutide is FDA-approved as Trulicity.
The approved uses are:
- As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus.
- To reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Dulaglutide is not FDA-approved for:
- Obesity
- Cosmetic weight loss
- Type 1 diabetes
- Diabetic ketoacidosis
- Prediabetes alone
- Anti-aging
- Bodybuilding
- Athletic performance
- General appetite suppression
- Longevity
- General wellness
The key distinction:
Dulaglutide is an approved diabetes and cardiovascular-risk drug, not an approved weight-loss drug.
Is Dulaglutide legal?
Dulaglutide’s legal status depends on product type, jurisdiction, prescription status, and intended use.
For U.S. readers:
Trulicity is a prescription medication. Online dulaglutide products, compounded GLP-1 products, or “research use only” dulaglutide are not the same as FDA-approved Trulicity.
The practical distinction:
| Product type | What it means |
|---|---|
| Trulicity | FDA-approved dulaglutide prescription product. |
| Generic dulaglutide | Not the same as Trulicity unless lawfully approved and dispensed. |
| Compounded GLP-1 product | Not equivalent to FDA-approved Trulicity unless properly prescribed and legally compounded under applicable rules. |
| Research-use dulaglutide | Not an FDA-approved consumer therapeutic product. |
| Online GLP-1 peptide | Higher risk for identity, purity, sterility, dose, and safety problems. |
The blunt version:
Buying “research use only” dulaglutide online is not the same as receiving FDA-approved Trulicity from a legitimate pharmacy.
Is Dulaglutide banned in sports?
Dulaglutide is a GLP-1 receptor agonist. GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists.
The USADA GLP-1 athlete guide says GLP-1 drugs are not currently prohibited in sport, but WADA is monitoring and evaluating GLP-1 agonist use by athletes.
The WADA GLP-1 receptor agonist monitoring research page discusses monitoring of GLP-1 receptor agonists including semaglutide and liraglutide.
The practical advice:
Athletes should verify dulaglutide through Global DRO, WADA, or USADA before use and should avoid unapproved online GLP-1 products.
Safety and side effects
Dulaglutide has real pharmacologic activity. It should not be treated like a harmless peptide.
Common or important risks include:
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Constipation
- Indigestion
- Decreased appetite
- Fatigue
- Injection-site reactions
- Hypoglycemia when used with insulin or sulfonylureas
- Dehydration from severe vomiting or diarrhea
- Acute kidney injury or worsening kidney function, especially with dehydration
- Pancreatitis
- Gallbladder disease
- Severe gastrointestinal reactions
- Diabetic retinopathy complications in some contexts
- Serious hypersensitivity reactions
- Possible thyroid C-cell tumor risk based on animal data
The boxed warning matters.
Dulaglutide is contraindicated in people with:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Serious hypersensitivity to dulaglutide or any product component
Dulaglutide is not recommended for:
- Type 1 diabetes
- Diabetic ketoacidosis
- Severe gastrointestinal disease, including severe gastroparesis
A serious evaluation of dulaglutide should separate:
| Product type | Risk profile |
|---|---|
| FDA-approved Trulicity | Prescription dulaglutide with regulated manufacturing, labeling, and clinical evidence. |
| Properly prescribed dulaglutide | Medical supervision and pharmacy dispensing. |
| Online research-use dulaglutide | High risk for identity, purity, sterility, concentration, dosing, and legal problems. |
| Compounded GLP-1 products | May carry quality and regulatory risks depending on source, formulation, and compliance. |
Dulaglutide vs similar GLP-1 drugs and peptides
| Compound | Category | Main difference |
|---|---|---|
| Dulaglutide / Trulicity | GLP-1 receptor agonist | Once-weekly FDA-approved diabetes drug with cardiovascular-risk reduction indication in certain adults with type 2 diabetes. |
| Semaglutide / Ozempic | GLP-1 receptor agonist | FDA-approved for type 2 diabetes and cardiovascular-risk reduction in certain patients; semaglutide also has separate obesity product Wegovy. |
| Semaglutide / Wegovy | GLP-1 receptor agonist | FDA-approved chronic weight-management product, unlike dulaglutide. |
| Liraglutide / Victoza | GLP-1 receptor agonist | Once-daily diabetes GLP-1 drug. |
| Liraglutide / Saxenda | GLP-1 receptor agonist | Once-daily obesity GLP-1 drug. |
| Tirzepatide / Mounjaro | GIP/GLP-1 receptor agonist | FDA-approved for type 2 diabetes; dual receptor mechanism. |
| Tirzepatide / Zepbound | GIP/GLP-1 receptor agonist | FDA-approved for chronic weight management and other specific indications. |
| Exenatide | GLP-1 receptor agonist | Older exendin-based GLP-1 drug, different structure and dosing. |
| Lixisenatide | GLP-1 receptor agonist | Once-daily GLP-1 drug for type 2 diabetes. |
| Retatrutide | Triple GIP/GLP-1/glucagon agonist | Investigational, not FDA-approved. |
| Cagrilintide | Amylin analog | Investigational amylin analog, not a GLP-1 agonist. |
The key distinction:
Dulaglutide is an approved GLP-1 diabetes drug with cardiovascular evidence, but it is not the same as Wegovy, Zepbound, Ozempic, Mounjaro, or research-use GLP-1 peptides.
Why is Dulaglutide sold as “research use only”?
Some online sellers may use “research use only” language to sell dulaglutide or GLP-1-like peptides outside normal prescription channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Trulicity | FDA-approved prescription dulaglutide product. |
| FDA-approved dulaglutide | Exists as Trulicity for specific uses. |
| Research-use dulaglutide | Not an FDA-approved consumer therapeutic product. |
| Online GLP-1 peptide | Higher risk for identity, purity, sterility, dose, and authenticity problems. |
| “Weight-loss dulaglutide” | Misleading because dulaglutide is not FDA-approved as an obesity medication. |
How to evaluate Dulaglutide claims online
| Claim | What to verify |
|---|---|
| “FDA-approved dulaglutide” | True for Trulicity’s approved type 2 diabetes and cardiovascular-risk indications. |
| “Dulaglutide is FDA-approved for weight loss” | False. It is not approved for obesity or cosmetic weight loss. |
| “Same as Ozempic” | False. Both are GLP-1 receptor agonists, but dulaglutide and semaglutide are different drugs. |
| “Same as Wegovy” | False. Wegovy is semaglutide and is obesity-approved. Trulicity is dulaglutide and is diabetes-approved. |
| “Same as Mounjaro” | False. Mounjaro is tirzepatide, a GIP/GLP-1 agonist. |
| “No thyroid risk” | False. Dulaglutide has a boxed warning for thyroid C-cell tumors based on animal data. |
| “Safe for everyone” | False. Contraindications and serious risks matter. |
| “Good for type 1 diabetes” | False. It is not for type 1 diabetes or diabetic ketoacidosis. |
| “Research use only” | This does not mean safe, legal, approved, or equivalent to Trulicity. |
| “Cheap dulaglutide online” | High risk. Product identity, sterility, purity, dose, and safety may be unknown. |
| “Safe for athletes” | Verify through WADA, USADA, or Global DRO. GLP-1 rules can change. |
Bottom line
Dulaglutide is an FDA-approved once-weekly GLP-1 receptor agonist sold as Trulicity. It has strong evidence for improving glycemic control in type 2 diabetes and reducing major cardiovascular event risk in certain adults with type 2 diabetes.
The most defensible conclusion is:
Dulaglutide is a legitimate prescription diabetes drug with cardiovascular-outcomes evidence, not a casual weight-loss peptide. It is not FDA-approved for obesity, anti-aging, bodybuilding, or general appetite suppression. Readers should distinguish regulated Trulicity from unapproved online or research-use dulaglutide products with uncertain identity, purity, sterility, concentration, and legal status.
FAQ
What is Dulaglutide?
Dulaglutide is a once-weekly GLP-1 receptor agonist used to improve glycemic control in type 2 diabetes. It is sold under the brand name Trulicity.
What is Trulicity?
Trulicity is the FDA-approved brand name for dulaglutide injection.
Is Dulaglutide FDA-approved?
Yes. Dulaglutide is FDA-approved as Trulicity to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes and to reduce major cardiovascular event risk in certain adults with type 2 diabetes.
Is Dulaglutide FDA-approved for weight loss?
No. Dulaglutide is not FDA-approved as an obesity or chronic weight-management medication.
How does Dulaglutide work?
Dulaglutide activates GLP-1 receptors. It increases glucose-dependent insulin secretion, reduces glucagon secretion, slows gastric emptying, and promotes satiety.
Is Dulaglutide the same as Ozempic?
No. Ozempic contains semaglutide. Dulaglutide and semaglutide are both GLP-1 receptor agonists, but they are different drugs.
Is Dulaglutide the same as Wegovy?
No. Wegovy is semaglutide and is FDA-approved for chronic weight management. Dulaglutide is Trulicity and is not FDA-approved for weight loss.
Is Dulaglutide the same as Mounjaro?
No. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Dulaglutide is a GLP-1 receptor agonist.
Does Dulaglutide reduce cardiovascular risk?
Yes. Dulaglutide is FDA-approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Can children use Dulaglutide?
Dulaglutide is FDA-approved to improve glycemic control in pediatric patients 10 years and older with type 2 diabetes. Safety and effectiveness are not established in children under 10.
Is Dulaglutide safe?
Dulaglutide has FDA-reviewed safety data, but it is not risk-free. Risks include gastrointestinal side effects, hypoglycemia with insulin or sulfonylureas, pancreatitis, gallbladder disease, kidney injury from dehydration, hypersensitivity, and a boxed warning related to thyroid C-cell tumors.
Who should not use Dulaglutide?
Dulaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma, people with multiple endocrine neoplasia syndrome type 2, and people with serious hypersensitivity to dulaglutide or product components.
Is Dulaglutide legal in the U.S.?
Trulicity is a prescription FDA-approved dulaglutide product for specific indications. Online dulaglutide or research-use GLP-1 products are not the same as FDA-approved Trulicity.
Is Dulaglutide banned in sports?
GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Athletes should verify current status through WADA, USADA, or Global DRO before use.
Why do sellers call Dulaglutide “research use only”?
Sellers often use “research use only” language when their dulaglutide or GLP-1 product is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or equivalent to Trulicity.
What is the biggest risk with Dulaglutide?
The biggest risks are using dulaglutide without proper medical supervision, confusing Trulicity with weight-loss GLP-1 drugs, ignoring contraindications and boxed warnings, and buying online products with uncertain identity, purity, sterility, concentration, and safety.
Sources
- DailyMed: Trulicity, dulaglutide injection label
- DailyMed: Trulicity Medication Guide
- FDA: Trulicity Prescribing Information PDF
- Mayo Clinic: Dulaglutide subcutaneous route
- MedlinePlus: Dulaglutide Injection
- PubMed: Dulaglutide and cardiovascular outcomes in type 2 diabetes, REWIND
- Lancet: Dulaglutide and cardiovascular outcomes in type 2 diabetes, REWIND
- PubMed: Once-weekly dulaglutide for treatment of youths with type 2 diabetes
- NEJM: Once-weekly dulaglutide for treatment of youths with type 2 diabetes
- PubMed: Once-weekly dulaglutide versus once-daily liraglutide, AWARD-6
- PubMed: Once-weekly dulaglutide versus insulin glargine, AWARD-2
- PMC: Once-weekly dulaglutide added on to glimepiride, AWARD-8
- PubMed: Dulaglutide as add-on therapy to SGLT2 inhibitors, AWARD-10
- PubMed: Effect of dulaglutide on stroke, exploratory REWIND analysis
- USADA: Weight Loss Drugs, What Athletes Need to Know About GLP-1s
- WADA: GLP-1 Receptor Agonists Monitoring Research
- WADA: Prohibited List
Frequently asked questions
What is Dulaglutide?
Dulaglutide is a once-weekly GLP-1 receptor agonist used to improve glycemic control in type 2 diabetes. It is sold under the brand name Trulicity.
What is Trulicity?
Trulicity is the FDA-approved brand name for dulaglutide injection.
Is Dulaglutide FDA-approved?
Yes. Dulaglutide is FDA-approved as Trulicity to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes and to reduce major cardiovascular event risk in certain adults with type 2 diabetes.
Is Dulaglutide FDA-approved for weight loss?
No. Dulaglutide is not FDA-approved as an obesity or chronic weight-management medication.
How does Dulaglutide work?
Dulaglutide activates GLP-1 receptors. It increases glucose-dependent insulin secretion, reduces glucagon secretion, slows gastric emptying, and promotes satiety.
Is Dulaglutide the same as Ozempic?
No. Ozempic contains semaglutide. Dulaglutide and semaglutide are both GLP-1 receptor agonists, but they are different drugs.
Is Dulaglutide the same as Wegovy?
No. Wegovy is semaglutide and is FDA-approved for chronic weight management. Dulaglutide is Trulicity and is not FDA-approved for weight loss.
Does Dulaglutide reduce cardiovascular risk?
Yes. Dulaglutide is FDA-approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Can children use Dulaglutide?
Dulaglutide is FDA-approved to improve glycemic control in pediatric patients 10 years and older with type 2 diabetes. Safety and effectiveness are not established in children under 10.
Is Dulaglutide safe?
Dulaglutide has FDA-reviewed safety data, but it is not risk-free. Risks include gastrointestinal side effects, hypoglycemia with insulin or sulfonylureas, pancreatitis, gallbladder disease, kidney injury from dehydration, hypersensitivity, and a boxed warning related to thyroid C-cell tumors.
Who should not use Dulaglutide?
Dulaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma, people with multiple endocrine neoplasia syndrome type 2, and people with serious hypersensitivity to dulaglutide or product components.
Is Dulaglutide banned in sports?
GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Athletes should verify current status through WADA, USADA, or Global DRO before use.
Sources
- [1]
- [2]DailyMed: Trulicity Medication Guide
Drug Label
- [3]
- [4]Mayo Clinic: Dulaglutide subcutaneous route
Medical Reference
- [5]MedlinePlus: Dulaglutide Injection
Medical Reference
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]WADA: Prohibited List
Anti Doping
Last updated May 9, 2026